A Phase 3 interventional study of BDB-001 injection and Cyclophosphamide in ANCA Associated Vasculitis (AAV), sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Recruiting at 65 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China — 42 open to participants now, 46 under way, 1 of them phase 3. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · China.
Among the 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China, this one has the largest planned enrollment of the 52 interventional ones that give a count, is one of 21 that started in 2025, is the only one in phase 3, reaches primary completion later than 21 of the 45 other live ones, and was the 41st registered.
158 studies on the registry are indexed under Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; 76 are open to participants now.
Browse Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis studies →42 of the 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China are open now. Recruiting first, the newest first:
Chinese PLA General Hospital · Sites in China
Ages 18+
The Children's Hospital of Zhejiang University School of Medicine · Sites in China
Ages 3+
Shanghai Changzheng Hospital · Sites in China
Ages 18–65
Changhai Hospital · Sites in China
Ages 18–70
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 56 Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis studies recruiting now, 21 (38%) set no upper age limit and 28 (50%) stop at 75 or younger; 9 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 8 · Phase 3 1 · Phase 4 3
First in 2014; this study’s year is marked. 21 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 36 across 117 interventional studies indexed under Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
Median enrollment 18 across the 52 interventional studies, 80 across the 5 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 57 have an industry lead sponsor. The 10 most frequent:
Staidson (Beijing) Biopharmaceuticals Co., Ltd is the lead sponsor of 28 studies on the registry; 5 are open to participants now.
Staidson (Beijing) Biopharmaceuticals Co., Ltd has 3 studies filed under Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis — fewer than ten, so there is no comparison to draw.
20 of the studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07168161Phase 3Staidson (Beijing) Biopharmaceuticals Co., LtdBDB-001 Phase III Trial in ANCA-Associated Vasculitis | 2027-04-16 |
| NCT07236762China Immunotech (Beijing) Biotechnology Co., Ltd.An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases | 2026-11-24 |
| NCT06388941Novartis PharmaceuticalsIptacopan in Patients With ANCA Associated Vasculitis | 2026-12-30 |
| NCT07033299Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyThe Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis | 2026-12-31 |
| NCT06285279Nanjing University School of MedicineThe BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases | 2026-12-31 |
Add all 20 to your calendar (.ics) → With an account.
Among the 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary aim is to study the efficacy of treatment with BDB-001 Injection to induce remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BDB-001 injection plus cyclophosphamide/azathioprine or rituximab plus prednisone-matching placebo.
Drug: BDB-001 injection · Drug: Cyclophosphamide · Drug: Rituximab · Drug: Azathioprine
BDB-001 injection-matching placebo plus cyclophosphamide/azathioprine or rituximab plus a full starting dose of prednisone.
Drug: Cyclophosphamide · Drug: Rituximab · Drug: Azathioprine · Drug: Prednisone
Intravenously administered
Intravenously administered
Intravenously administered
Intravenously administered
Intravenously administered
The proportion of patients achieving disease remission assessed by Birmingham Vasculitis Activity Score (BVAS)
Time frame: Week 24
The proportion of patients achieving disease sustained remission assessed by Birmingham Vasculitis Activity Score (BVAS)
Time frame: Week 48
Percentage of Subjects and Time to Experiencing a Relapse After Previously Achieving Remission in the Study
Time frame: Week 48
Percentage of Participants With BVAS of 0 at Week 4
Time frame: Week 4
In Subjects With Renal Disease at Baseline (Based in the BVAS Renal Component), Change from baseline in Estimated glomerular filtration rate (eGFR)
Time frame: Baseline, Week 24 and Week 48
In Subjects With Renal Disease at Baseline (Based in the BVAS Renal Component), Change from baseline in Urinary albumin:creatinine ratio (UACR)
Time frame: Baseline, Week 4, 24 and 48
Glucocorticoid-induced Toxicity as Measured by Change From Baseline in the GTI
Time frame: Baseline, Week 24 and 48
Cumulative dose of glucocorticoids
Time frame: Week 24 and 48
Change from baseline in the Vasculitis Damage Index (VDI)
Time frame: Baseline, Week 24 and 48
Change From Baseline in Health-related Quality of Life as Measured by the Domains and Component Scores of the SF-36
Time frame: Baseline, Week 24 and 48
Started Nov 2025 (actual). Primary completion is estimated for Apr 2027, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BDB001
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis →
Staidson (Beijing) Biopharmaceuticals Co., Ltd →